Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Nov 28;11(11):e0167181.
doi: 10.1371/journal.pone.0167181. eCollection 2016.

Features of Age-Related Macular Degeneration in the General Adults and Their Dependency on Age, Sex, and Smoking: Results from the German KORA Study

Affiliations

Features of Age-Related Macular Degeneration in the General Adults and Their Dependency on Age, Sex, and Smoking: Results from the German KORA Study

Caroline Brandl et al. PLoS One. .

Abstract

Age-related macular degeneration (AMD) is a vision impairing disease of the central retina characterized by early and late forms in individuals older than 50 years of age. However, there is little knowledge to what extent also younger adults are affected. We have thus set out to estimate the prevalence of early AMD features and late AMD in a general adult population by acquiring color fundus images in 2,840 individuals aged 25 to 74 years of the Cooperative Health Research in the Region of Augsburg project (KORA) in South Germany. Among the 2,546 participants with gradable images for each eye, 10.9% (n = 277) had early AMD features (applying the 9-step Age-Related Eye Disease Study Severity Scale), 0.2% (n = 6) had late AMD. Prevalence increased with age, reaching 26.3% for early AMD features and 1.9% for late AMD at the age 70+. However, signs of early AMD were found in subjects as young as 25 years, with the risk for early AMD features increasing linearly by years of age in men, and, less consistent with a linear increase, in women. Risk for early AMD features increased linearly by pack years of smoking in men, not in women, nor was there any association with other lifestyle or metabolic factors. By providing much sought-after prevalence estimates for AMD from Central Europe, our data underscores a substantial proportion of the adult population with signs of early AMD, including individuals younger than 50 years. This supports the notion that early AMD features in the young might be under-acknowledged.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: Author H.H. has received lecture honorarium, travel support and is a member of the advisory board of the companies Bayer AG (Leverkusen, Germany), Allergan (Dublin, Ireland), and Novartis Pharma GmbH (Nürnberg, Germany). All other authors have declared that no competing interests exist. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. The age-trend of early AMD risk modelled separately for men and women.
Shown is the modelled trend of early AMD relative risk by years of age utilizing a thin plate regression spline for A) men (n early AMD = 134, n AMD-free = 1,139) or B) women (n early AMD = 143, n AMD-free = 1,124). Relative risk is given as log odds ratio with persons at the age of 50 as reference and 95% confidence interval shaded in grey. The modelled trend was in line with a linear relationship for men (degrees of freedom = 1.001), but not for women (degrees of freedom = 3.283).

References

    1. Augood CA, Vingerling JR, de Jong PT, Chakravarthy U, Seland J, Soubrane G, et al. Prevalence of age-related maculopathy in older Europeans: the European Eye Study (EUREYE). ArchOphthalmol. 2006;124(4):529–35. - PubMed
    1. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. NEnglJMed. 2008;358(24):2606–17. - PubMed
    1. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet. 2012;379(9827):1728–38. 10.1016/S0140-6736(12)60282-7 - DOI - PubMed
    1. Young RW. Pathophysiology of age-related macular degeneration. SurvOphthalmol. 1987;31(5):291–306. - PubMed
    1. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. NEnglJMed. 2006;355(14):1432–44. - PubMed